Search

Health is a fundamental human right, and achieving equality in access to medicines is crucial for ensuring public health. The current system of innovation strongly relies on the private sector, while remuneration of innovation is mainly based on exclusivities. This system presents several issues, such as innovation being driven by market size, the partial misalignment between industry’s research and development (R&D) priorities and public health goals, access constraints, and the scarcity of disruptive ...

Algorithm-generated diets tailored to our individual needs could bring health benefits, but at the cost of having to share our most personal data, such as our DNA. The promises are many, but so are the open questions about interactions between genes, nutrients, environment and health, and the role of socioeconomic factors underlying food choices. Precision nutrition advice, services and products will need to be governed by a range of laws and policies, as they are at the intersection between food ...

Most rare diseases are incurable. Research into new diagnostics and therapies is hampered by the low number of patients, limited amount of data, lack of multi-centre coordination and low profitability. Biosensors are a technology that, driven by continuous advances in artificial intelligence, can help disease detection, lower the cost of novel therapies, replace placebo groups in clinical trials and foster patient-centred, personalised (e)-medicine. Governance of biosensor technology involves targeted ...

Antimicrobial resistance (AMR) is a global, multidimensional phenomenon occurring in humans, animals, and environmental ecosystems. It is the ability of microbes, e.g. bacteria, viruses, fungi and protozoa, to survive in the presence of medicines designed to kill or inactivate them (antimicrobials: antibiotics, antivirals, antifungals and antiprotozoals). At patient level, AMR hampers the effective treatment of microbial infections, leading to prolonged, severe disease and, in some cases, death. ...

The European Commission plans to launch its revised EU pharmaceutical package in the first quarter of 2023. Ahead of its release, two recent STOA studies offer insight to inform upcoming Parliamentary discussions. Fragmentation of EU health research and development, lack of transparency and a translation gap between public investment and clinical output are among the weaknesses identified. Possible solutions include the creation of large-scale European biomedical infrastructure, and a series of targeted ...

Quantum technologies could be a game-changer in the digital transformation of health care. By enabling much faster and more complex data analysis, they could open the door to the accelerated discovery and development of novel therapeutics, improved diagnostics and treatments, including for rare and complex diseases, genuinely personalised medicine, and better data-driven health policy planning. However, as is also the case in other sectors, quantum technologies come with risks, particularly to cybersecurity ...

Antimicrobial-resistant infections are predicted to become the second biggest cause of death worldwide by 2050. Despite increasing investment in the development of new antimicrobials, awareness campaigns on antimicrobial misuse and abuse, and monitoring of antimicrobial use and resistance in animals, humans and the environment, antimicrobial resistance continues to grow and the last three decades have not seen even one novel antimicrobial class reach the market. Could the answer lie in a 'Trojan ...

The COVID 19 pandemic prompted reinforced investment in health research, to support rapid research and innovation for vaccine development and health care measures. The European Union response highlighted strengths and weaknesses in EU research organisation and funding. Over time, EU investment in health research has been aimed at increasing knowledge and transfer of knowledge into innovation, for better health. To this end, several instruments have been developed, but the impact of these efforts ...

Demographic, socio-political and economic pressures have made eating meat an unsustainable practice for the long term. However, meat substitutes have proved unpopular, owing to social norms and a lack of trust; some alternatives also contribute heavily to climate change. Could microbial protein be a sustainable alternative to meat that not only solves these multidimensional pressures but also contributes actively to reversing climate change?

Genome editing is a powerful new tool allowing precise additions, deletions and substitutions in the genome. The development of new approaches has made editing of the genome much more precise, efficient, flexible, and less expensive, relative to previous strategies. As with other medical advances, each such application comes with its own set of benefits, risks, ethical issues and societal implications, which may require new regulatory frameworks. Important questions raised with respect to genome ...